{"entity":{"id":"nct04270591","kind":"trial","name":"Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer","aka":[],"tldr":"A phase 1/2 trial of Glumetinib in non-small-cell lung cancer, run by Haihe Biopharma Co., Ltd., now recruiting.","summary":"Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT04270591 by Haihe Biopharma Co., Ltd., with 183 participants planned, started 2019-07-15 and due to reach its primary completion in 2023-10-25. Interventions recorded: Glumetinib.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04270591","url":"https://clinicaltrials.gov/study/NCT04270591"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["glumetinib"],"companies":["haihe-biopharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04270591","phase":"1/2","setting":"A Phase Ib/II, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Glumetinib (SCC244), a Selective MET Inhibitor in Patients With Advanced Non-Small Cell Lung Cancer Harboring MET-alterations","sponsor":"Haihe Biopharma Co., Ltd.","enrolled":183,"outcomes":[]},"route":"/trials/nct04270591/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"glumetinib","kind":"drug","name":"Glumetinib","route":"/drugs/glumetinib/"}],"company":[{"id":"haihe-biopharma","kind":"company","name":"Haihe Biopharma","route":"/companies/haihe-biopharma/"}]}}